Raia Drogasil (BSP:RADL3) Piotroski F-Score: 7 (As of Jun. 27, 2026) — 40% Above Median


BSP:RADL3 Raia Drogasil SA BSP:RADL3
91 GF Score
Price R$17.35
GF Value R$29.94
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Raia Drogasil Piotroski F-Score?

Raia Drogasil BSP:RADL3 +0.87% 91 Piotroski F-Score is 7 as of Jun. 27, 2026, which is 40% above its 10-year median of 5.00. GuruFocus rates BSP:RADL3 with a GF Score™ of 91/100 and a GF Value™ of R$29.94 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 652 Healthcare Providers & Services companies, Raia Drogasil ranks better than 88.8% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Raia Drogasil has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Raia Drogasil's Piotroski F-Score or its related term are showing as below:

BSP:RADL3' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Raia Drogasil was 8. The lowest was 3. And the median was 5.

Raia Drogasil  (BSP:RADL3) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Raia Drogasil Piotroski F-Score Related Terms


Raia Drogasil Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Raia Drogasil's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Raia Drogasil Piotroski F-Score Chart

Raia Drogasil Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 7.00 5.00 4.00 6.00

Raia Drogasil Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 6.00 6.00 7.00

Raia Drogasil Piotroski F-Score Competitor Comparison

For the Pharmaceutical Retailers subindustry, Raia Drogasil's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raia Drogasil Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Raia Drogasil's Piotroski F-Score falls into.


BSP:RADL3
91GF Score
Raia Drogasil SA BSP:RADL3
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 374.004 + 453.972 + 304.918 + 158.956 = R$1,292 Mil.
Cash Flow from Operations was 495.93 + 995.102 + -502.872 + 769.602 = R$1,758 Mil.
Revenue was 10831.043 + 11264.916 + 12103.481 + 10568.589 = R$44,768 Mil.
Gross Profit was 3200.886 + 3315.806 + 3564.93 + 3394.3 = R$13,476 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(22633.253 + 23052.47 + 23825.807 + 25170.475 + 25272.166) / 5 = R$23990.8342 Mil.
Total Assets at the begining of this year (Mar25) was R$22,633 Mil.
Long-Term Debt & Capital Lease Obligation was R$7,251 Mil.
Total Current Assets was R$15,357 Mil.
Total Current Liabilities was R$10,456 Mil.
Net Income was 326.631 + 335.016 + 350.402 + 163.967 = R$1,176 Mil.

Revenue was 9687.22 + 9989.122 + 10094.686 + 9272.963 = R$39,044 Mil.
Gross Profit was 2931.999 + 2970.912 + 2994.606 + 2822.047 = R$11,720 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(20651.653 + 20705.524 + 21955.996 + 22163.756 + 22633.253) / 5 = R$21622.0364 Mil.
Total Assets at the begining of last year (Mar24) was R$20,652 Mil.
Long-Term Debt & Capital Lease Obligation was R$5,992 Mil.
Total Current Assets was R$13,108 Mil.
Total Current Liabilities was R$9,746 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Raia Drogasil's current Net Income (TTM) was 1,292. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Raia Drogasil's current Cash Flow from Operations (TTM) was 1,758. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=1291.85/22633.253
=0.05707752

ROA (Last Year)=Net Income/Total Assets (Mar24)
=1176.016/20651.653
=0.05694537

Raia Drogasil's return on assets of this year was 0.05707752. Raia Drogasil's return on assets of last year was 0.05694537. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Raia Drogasil's current Net Income (TTM) was 1,292. Raia Drogasil's current Cash Flow from Operations (TTM) was 1,758. ==> 1,758 > 1,292 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=7250.78/23990.8342
=0.30223126

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=5991.779/21622.0364
=0.27711446

Raia Drogasil's gearing of this year was 0.30223126. Raia Drogasil's gearing of last year was 0.27711446. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=15356.757/10455.551
=1.46876592

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=13107.724/9746.165
=1.34491095

Raia Drogasil's current ratio of this year was 1.46876592. Raia Drogasil's current ratio of last year was 1.34491095. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Raia Drogasil's number of shares in issue this year was 1693.026. Raia Drogasil's number of shares in issue last year was 1687.387. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=13475.922/44768.029
=0.30101665

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=11719.564/39043.991
=0.30016306

Raia Drogasil's gross margin of this year was 0.30101665. Raia Drogasil's gross margin of last year was 0.30016306. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=44768.029/22633.253
=1.9779759

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=39043.991/20651.653
=1.89059883

Raia Drogasil's asset turnover of this year was 1.9779759. Raia Drogasil's asset turnover of last year was 1.89059883. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Raia Drogasil has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Raia Drogasil (BSP:RADL3) has a Piotroski F-Score of 7 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Raia Drogasil and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, Raia Drogasil's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Raia Drogasil ranks #73 out of 652 companies in the Healthcare Providers & Services industry, placing it in the top 11.2%.
Is Raia Drogasil's Piotroski F-Score too high?
Raia Drogasil's current Piotroski F-Score of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Raia Drogasil's value of 7 is 40% above this industry median. Based on the distribution chart, Raia Drogasil ranks #73 out of 652 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Raia Drogasil has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's Piotroski F-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #73 out of 652 companies for Piotroski F-Score. This places Raia Drogasil in the top 11% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Raia Drogasil's value of 7 is 40% above this benchmark. Historically, Raia Drogasil's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Raia Drogasil has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 652 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current Piotroski F-Score is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$29.94, compared to a current price of R$17.35 — trading 42.1% below its estimated fair value. The current Piotroski F-Score is 7, which is 40% above median its 10-year median of 5.00 and 40% above the Healthcare Providers & Services industry median of 5.00. Raia Drogasil's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current Piotroski F-Score is 7 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?

Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued. The current stock price of R$17.35 is trading 42.1% below its estimated GF Value™ of R$29.94. GuruFocus considers Raia Drogasil to be Significantly Undervalued.

Key valuation signals for BSP:RADL3:

  • Piotroski F-Score: 7 (40% above median its 10-year median of 5.00)
  • GF Value™: R$29.94 vs. price of R$17.35 (42.1% below fair value)
  • GF Score™: 91/100 with 3 warning signs
  • Industry Position: 40% above the Healthcare Providers & Services median (#73 of 652)

No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Raia Drogasil Business Description

Other Exchanges RADLY:USA
Address Avenue Corifeu de Azevedo Marques, 3097 Butanta, Sao Paulo, SP, BRA, 05339-900
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
91GF Score

Get the complete analysis for BSP:RADL3

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$17.35
Price
R$29.94
GF Value